Not surprisingly, dysfunction of GSK3β has been implicated in a wide array of neuropsychiatric and neurological disorders, including mood disorder [34,35,36,37,38], schizophrenia [39,40,41,42,43], Alzheimer’s disease [44,45,46,47], Parkinson’s disease [48,49], and substance use disorder [50], raising a tremendous interest in targeting this kinase and its signaling pathways for neurotherapeutic development. The gene discussed is GSK3B; the disease is Parkinson disease.